Reandron testosterone is changing brand to Gonadron
Your testosterone undecanoate Reandron is changing to Gonadron.
Same medicine with the same active ingredient
Gonadron has the same active ingredient, in the same quantity, as Reandron. All the ingredients remain the same, including the excipients - which are the inactive ingredients. You should not notice any difference in how it works.
Gonadron brand listed (funded) from 1 June 2026
The Gonadron brand of testosterone undecanoate injection (250 mg per ml) will be listed from 1 June 2026.
- Chemical: Testosterone undecanoate
- Presentation: Inj 250 mg per ml
- Brand: Gonadron
- Pharmacode: 2721368
- Measure / Qty: 4 ml vial (1000 mg)
When is this happening
Gonadron will be listed from 1 June 2026, Reandron will stop being funded from 1 November 2026. You will notice your brand will change sometime between 1 June and 1 November.
Key dates
1 June 2026 | Gonadron (Pharmacode: 2721368) Listed - funded.
1 November 2026 | Reandron (Pharmacode: 2472716) Delisted - no longer funded.
Testosterone undecanoate | Community schedule(external link)
Why is this happening?
This is a tender brand change. Every year, Pharmac runs a tender process to create competition among suppliers who supply the many medicines used by New Zealanders.
The tender helps Pharmac manage the costs of medicines. Any savings we make are returned to the medicines budget to help pay for new medicines.
This brand change is helping fund more medicines for more New Zealanders.
About the annual tender process
Who to contact
If you have questions about this issue, email enquiry@pharmac.govt.nz
Please include as much information as you can about the product (presentation, brand, pharmacode) and who your wholesaler is.